Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma

Cardio-Oncology
Eric H YangGary J Schiller

Abstract

Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM). However, there are reports of adverse cardiac events with carfilzomib manifested by dyspnea and heart failure. A patient is presented who had recurrent, clinically mild cardiotoxicity, as manifested by recurrent heart failure with preserved ejection fraction, with ongoing maintenance carfilzomib in a patient with resistant MM is presented.

References

Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
May 31, 2012·Blood·Philippe MoreauJean-Luc Harousseau
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Jan 16, 2016·Blood Cancer Journal·A RosenthalA K Stewart
Mar 2, 2016·Circulation·Weijuan LiJavid Moslehi

❮ Previous
Next ❯

Citations

Jun 10, 2020·Current Oncology Reports·Perry WuEric H Yang
Sep 19, 2020·Cardio-Oncology·Arnold Méndez-ToroEstivalis Acosta-Gutiérrez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.